Detalhe da pesquisa
1.
TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer.
Proc Natl Acad Sci U S A
; 118(38)2021 09 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34518220
2.
AST-487 Inhibits RET Kinase Driven TERT Expression in Bladder Cancer.
Int J Mol Sci
; 23(18)2022 Sep 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36142729
3.
High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes.
Int J Mol Sci
; 23(18)2022 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36142576
4.
FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.
BJU Int
; 123(1): 187-196, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30120861
5.
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.
Ann Hematol
; 94(12): 2015-24, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26385387
6.
Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer.
Oncogene
; 40(16): 2884-2897, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33742123
7.
Subtype specific expression and survival prediction of pivotal lncRNAs in muscle invasive bladder cancer.
Sci Rep
; 10(1): 20472, 2020 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33235218
8.
First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer.
Mol Cancer Ther
; 19(8): 1598-1612, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32499299
9.
FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy.
J Clin Med
; 9(4)2020 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32252315
10.
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
Leukemia
; 34(10): 2823, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32913312
11.
High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
Leukemia
; 34(8): 2074-2086, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32382082
12.
Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.
PLoS One
; 14(3): e0214305, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30897165
13.
Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer.
J Med Chem
; 62(22): 10182-10203, 2019 11 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31675229
14.
FOXM1 predicts disease progression in non-muscle invasive bladder cancer.
J Cancer Res Clin Oncol
; 144(9): 1701-1709, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29959570
15.
Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening.
Oncotarget
; 9(40): 25935-25945, 2018 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29899832
16.
The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia.
PLoS One
; 13(4): e0196326, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29689094
17.
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.
Leukemia
; 32(5): 1222-1228, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29479070
18.
Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.
Clin Lymphoma Myeloma Leuk
; 18(4): 266-271, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29510895
19.
FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes.
Oncotarget
; 8(29): 47595-47606, 2017 Jul 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28498805